CANbridge Pharmaceutical Inc that is focused on rare disease therapies has raised $98 million in its Series D round led by global private equity firm General Atlantic and existing investor WuXi AppTec, a Hong Kong and Shanghai dual-listed innovative drug maker, according to a company statement.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
